FY2024 EPS Estimates for Affimed (NASDAQ:AFMD) Lifted by Cantor Fitzgerald

Affimed (NASDAQ:AFMDFree Report) – Equities researchers at Cantor Fitzgerald increased their FY2024 earnings estimates for Affimed in a research report issued to clients and investors on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the biopharmaceutical company will post earnings of ($3.20) per share for the year, up from their prior forecast of ($4.90). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Affimed’s current full-year earnings is ($5.92) per share.

A number of other equities analysts also recently issued reports on AFMD. StockNews.com began coverage on shares of Affimed in a report on Tuesday, January 2nd. They issued a “sell” rating on the stock. Wells Fargo & Company dropped their price objective on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday. Finally, HC Wainwright raised their price objective on shares of Affimed to $10.00 and gave the stock a “buy” rating in a report on Monday. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $45.00.

Check Out Our Latest Analysis on Affimed

Affimed Stock Performance

Shares of AFMD stock opened at $6.66 on Thursday. The company has a 50 day moving average price of $5.48 and a 200-day moving average price of $4.92. Affimed has a 52 week low of $2.23 and a 52 week high of $11.10. The firm has a market capitalization of $101.43 million, a PE ratio of -0.79 and a beta of 2.05. The company has a quick ratio of 3.67, a current ratio of 3.70 and a debt-to-equity ratio of 0.10.

Hedge Funds Weigh In On Affimed

Several large investors have recently added to or reduced their stakes in the company. Vestal Point Capital LP purchased a new position in Affimed during the fourth quarter valued at approximately $341,000. BNP Paribas Financial Markets lifted its holdings in Affimed by 39.9% during the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 163,162 shares in the last quarter. EWA LLC purchased a new position in Affimed during the fourth quarter valued at approximately $89,000. abrdn plc purchased a new position in Affimed during the fourth quarter valued at approximately $130,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Affimed during the second quarter valued at approximately $129,000. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

(Get Free Report)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.

See Also

Earnings History and Estimates for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.